Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Behçet’s syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trialRosaria Talarico, Nazzareno Italiano, Giacomo Emmi, Matteo Piga, Luca Cantarini, Irene Mattioli, Alberto Floris, Stefano Gentileschi, Federica Di Cianni, Maria Letizia Urban, Emanuele Chiara, Diana Marinello, Alessandra Del Bianco, Michele Figus, Chiara PosarelliSee the full list of authors
17 October 2024
Behçet’s disease risk-variant HLA-B51/ERAP1-Hap10 alters human CD8 T cell immunityAnn Cavers, Matthias Christian Kugler, Yesim Ozguler, Arshed Fahad Al-Obeidi, Gulen Hatemi, Beatrix M Ueberheide, Didar Ucar, Olivier Manches, Johannes Nowatzky
3 August 2022
A unique circulating miRNA profile highlights thrombo-inflammation in Behçet’s syndromeGiacomo Emmi, Giacomo Bagni, Elena Lastraioli, Francesca Di Patti, Alessandra Bettiol, Claudia Fiorillo, Matteo Becatti, Elena Silvestri, Maria Letizia Urban, Lorenzo Emmi, Domenico Prisco, Annarosa Arcangeli
29 November 2021
Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behçet’s phenotype: a multicentre studyFilippo Fagni, Alessandra Bettiol, Rosaria Talarico, Giuseppe Lopalco, Elena Silvestri, Maria Letizia Urban, Paul A J Russo, Gerardo Di Scala, Giacomo Emmi, Domenico Prisco
7 May 2020
Critical role of neutrophil extracellular traps (NETs) in patients with Behcet’s diseaseAlexandre Le Joncour, Raphael Martos, Stephane Loyau, Nicolas Lelay, Antoine Dossier, Aurelie Cazes, Pierre Fouret, Fanny Domont, Thomas Papo, Martine Jandrot-Perrus, Marie-Christine Bouton, Patrice Cacoub, Nadine Ajzenberg, David Saadoun, Yacine Boulaftali
30 May 2019
